As of Tuesday, Health Catalyst Inc.’s (NASDAQ:HCAT) stock closed at $17.63, up from $16.99 the previous day. While Health Catalyst Inc. has overperformed by 3.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HCAT fell by -69.59%, with highs and lows ranging from $59.50 to $11.25, whereas the simple moving average fell by -37.52% in the last 200 days.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
On April 14, 2022, Guggenheim started tracking Health Catalyst Inc. (NASDAQ: HCAT) recommending Buy. A report published by Jefferies on March 17, 2022, Upgraded its rating to ‘Buy’ for HCAT. Goldman also rated HCAT shares as ‘Buy’, setting a target price of $48 on the company’s shares in an initiating report dated February 11, 2022. Jefferies Initiated an Hold rating on December 02, 2021, and assigned a price target of $48. BTIG Research initiated its ‘Buy’ rating for HCAT, as published in its report on October 14, 2021. JP Morgan’s report from April 29, 2021 suggests a price prediction of $63 for HCAT shares, giving the stock a ‘Overweight’ rating. Berenberg also rated the stock as ‘Buy’.
Analysis of Health Catalyst Inc. (HCAT)
Further, the quarter-over-quarter increase in sales is 22.00%, showing a positive trend in the upcoming months.
One of the most important indicators of Health Catalyst Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -32.20% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.20, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and HCAT is recording 999.81K average volume. On a monthly basis, the volatility of the stock is set at 6.53%, whereas on a weekly basis, it is put at 6.68%, with a gain of 12.29% over the past seven days. Furthermore, long-term investors anticipate a median target price of $25.00, showing growth from the present price of $17.63, which can serve as yet another indication of whether HCAT is worth investing in or should be passed over.
How Do You Analyze Health Catalyst Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.70%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 98.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in HCAT shares?
The recent increase in stakes in HCAT appears to be a result of several institutional investors and hedge funds increasing their positions. The Vanguard Group, Inc.’s position in HCAT has decreased by -1.20% in the first quarter. The company now owns 4,098,045 shares of the stock, with a value of $59.38 million, following the sale of -49,643 additional shares during the last quarter. AllianceBernstein LP made another increased to its shares in HCAT during the first quarter, upping its stake by 22.75%. During the last quarter, the company picked up 710,896 additional shares for a total stake of worth $55.58 million, bringing number of shares owned by the company to 3,835,775.
During the first quarter, Wellington Management Co. LLP added a 55,026 position in HCAT. Capital Research & Management Co sold an additional 0.0 shares in the last quarter, decreasing its holdings by 0.00%, now holding 3.39 million shares worth $49.15 million. At the end of the first quarter, BlackRock Fund Advisors increased its HCAT holdings by 2.53% and now holds 3.18 million HCAT shares valued at $46.03 million with the added 78508.0 shares during the period. HCAT shares are owned by institutional investors to the tune of 98.30% at present.